139 related articles for article (PubMed ID: 23862718)
21. Monoclonal antibodies in myeloma.
Sondergeld P; van de Donk NW; Richardson PG; Plesner T
Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
[TBL] [Abstract][Full Text] [Related]
22. Elotuzumab May Slow Multiple Myeloma.
Cancer Discov; 2015 Jul; 5(7):OF10. PubMed ID: 25998398
[No Abstract] [Full Text] [Related]
23. Zeroing in on cereblon.
Heaney ML
Eur J Haematol; 2015 Jul; 95(1):1-2. PubMed ID: 25777766
[No Abstract] [Full Text] [Related]
24. Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma.
Ray A; Das DS; Song Y; Hideshima T; Tai YT; Chauhan D; Anderson KC
Leukemia; 2018 Mar; 32(3):843-846. PubMed ID: 29104288
[No Abstract] [Full Text] [Related]
25. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Significance of Cereblon Expression in Patients With Multiple Myeloma.
Bila J; Sretenovic A; Jelicic J; Tosic N; Glumac I; Fekete MD; Antic D; Balint MT; Markovic O; Milojevic Z; Radojkovic M; Trajkovic G; Puric M; Pavlovic S; Mihaljevic B
Clin Lymphoma Myeloma Leuk; 2016 Nov; 16(11):610-615. PubMed ID: 27618360
[TBL] [Abstract][Full Text] [Related]
27. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.
Dalton WS; Grogan TM; Meltzer PS; Scheper RJ; Durie BG; Taylor CW; Miller TP; Salmon SE
J Clin Oncol; 1989 Apr; 7(4):415-24. PubMed ID: 2564428
[TBL] [Abstract][Full Text] [Related]
28. Daratumumab for the Treatment of Multiple Myeloma.
Plesner T; Krejcik J
Front Immunol; 2018; 9():1228. PubMed ID: 29915586
[TBL] [Abstract][Full Text] [Related]
29. DNA methyltransferase inhibitors upregulate CD38 protein expression and enhance daratumumab efficacy in multiple myeloma.
Choudhry P; Mariano MC; Geng H; Martin TG; Wolf JL; Wong SW; Shah N; Wiita AP
Leukemia; 2020 Mar; 34(3):938-941. PubMed ID: 31595037
[No Abstract] [Full Text] [Related]
30. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
Richardson P; Anderson K
J Clin Oncol; 2006 Jan; 24(3):334-6. PubMed ID: 16365174
[No Abstract] [Full Text] [Related]
31. Novel combination approaches for myeloma.
Lonial S; Nooka AK
Hematology Am Soc Hematol Educ Program; 2015; 2015():286-93. PubMed ID: 26637735
[No Abstract] [Full Text] [Related]
32. Evidence does not support clinically significant lenalidomide-CCI-779 interaction via P-glycoprotein.
Chen N; Kasserra C; Kumar G; Palmisano M
J Clin Oncol; 2012 Jan; 30(3):340-1; author reply 341-2. PubMed ID: 22162571
[No Abstract] [Full Text] [Related]
33. [Chemotherapy of multiple myeloma].
Estape J; Antón I; Daniels M; Bladé J; Domingo A; Rubio D
Sangre (Barc); 1984; 29(5):936-9. PubMed ID: 6523344
[No Abstract] [Full Text] [Related]
34. Lenalidomide affect expression level of cereblon protein in multiple myeloma cell line RPMI8226.
Yang DY; Ren JH; Guo XN; Guo XL; Cai XY; Guo XF; Zhang JN
Genet Mol Res; 2015 Oct; 14(4):13588-94. PubMed ID: 26535672
[TBL] [Abstract][Full Text] [Related]
35. Nonsecretion of myeloma protein in spite of an increase in tumor burden by chemotherapy.
Kubota K; Kurabayashi H; Kawada E; Okamoto K; Tamura J; Shirakura T
Ann Hematol; 1991 Oct; 63(4):232-3. PubMed ID: 1932306
[TBL] [Abstract][Full Text] [Related]
36. Lack of reversal with verapamil of drug resistance in multiple myeloma.
Mertens M; Thomas L; vd Lelie J
Br J Haematol; 1990 Sep; 76(1):155. PubMed ID: 2223640
[No Abstract] [Full Text] [Related]
37. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
Butrym A; Rybka J; Łacina P; Gębura K; Frontkiewicz D; Bogunia-Kubik K; Mazur G
Leuk Res; 2015 Dec; 39(12):1462-6. PubMed ID: 26521987
[TBL] [Abstract][Full Text] [Related]
38. A New Monoclonal Protein Detected in a Patient With Myeloma Undergoing Elotuzumab Therapy.
Tang F; Schmotzer C; Beck RC
JAMA Oncol; 2017 Dec; 3(12):1729-1730. PubMed ID: 28880973
[No Abstract] [Full Text] [Related]
39. XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.
Bagratuni T; Wu P; Gonzalez de Castro D; Davenport EL; Dickens NJ; Walker BA; Boyd K; Johnson DC; Gregory W; Morgan GJ; Davies FE
Blood; 2010 Jul; 116(2):250-3. PubMed ID: 20421453
[TBL] [Abstract][Full Text] [Related]
40. MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma.
de la Puente P; Muz B; Jin A; Azab F; Luderer M; Salama NN; Azab AK
Blood Cancer J; 2016 Feb; 6(2):e399. PubMed ID: 26918363
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
